{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:05:36Z","timestamp":1775570736395,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"DOI":"10.7759\/cureus.104904","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:39:24Z","timestamp":1773059964000},"source":"Crossref","is-referenced-by-count":1,"title":["Optimal Corticosteroid Therapy Based on Liver Biopsy for Severe Immune-Mediated Hepatitis During Pembrolizumab Treatment: A Case Report"],"prefix":"10.7759","author":[{"given":"Kotoba","family":"Esaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Awashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Kichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst RS","year":"2021","unstructured":"Herbst RS, Garon EB, Kim DW, et al.. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021, 16:1718-32. 10.1016\/j.jtho.2021.05.001","journal-title":"J Thorac Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and management of hepatitis in patients on checkpoint blockade","volume":"23","author":"Reynolds K","year":"2018","unstructured":"Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist. 2018, 23:991-7. 10.1634\/theoncologist.2018-0174","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin E","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, et al.. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018, 68:1181-90. 10.1016\/j.jhep.2018.01.033","journal-title":"J Hepatol"},{"key":"ref4","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). (2018). Accessed. February 20, 2026: https:\/\/www.cancer.gov\/research\/resources\/resource\/210."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000525","article-title":"Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: a systematic review and meta-analysis","volume":"8","author":"Hwang SY","year":"2024","unstructured":"Hwang SY, Hsieh P, Zhang W. Steroid-refractory immune checkpoint inhibitor (ICI) hepatitis and ICI rechallenge: a systematic review and meta-analysis. Hepatol Commun. 2024, 8:10.1097\/HC9.0000000000000525","journal-title":"Hepatol Commun"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4342","article-title":"Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer","volume":"7","author":"Li M","year":"2021","unstructured":"Li M, Sack JS, Bell P, Rahma OE, Srivastava A, Grover S, Zucker SD. Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer. JAMA Oncol. 2021, 7:1711-4. 10.1001\/jamaoncol.2021.4342","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17898","article-title":"An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury","volume":"59","author":"Riveiro-Barciela M","year":"2024","unstructured":"Riveiro-Barciela M, Barreira-D\u00edaz A, Salcedo MT, et al.. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury. Aliment Pharmacol Ther. 2024, 59:865-76. 10.1111\/apt.17898","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2957\/kanzo.66.375","article-title":"A guide for the diagnosis and treatment of immune checkpoint inhibitor-induced liver injury [Article in Japanese]","volume":"66","author":"Ito T","year":"2025","unstructured":"Ito T, Takeuchi Y, Mizuno K, et al.. A guide for the diagnosis and treatment of immune checkpoint inhibitor-induced liver injury [Article in Japanese]. Kanzo. 2025, 66:375-87. 10.2957\/kanzo.66.375","journal-title":"Kanzo"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama T","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, et al.. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020, 26:353-65. 10.3748\/wjg.v26.i3.353","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji L","year":"2023","unstructured":"Hountondji L, Ferreira De Matos C, Leboss\u00e9 F, et al.. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep. 2023, 5:100719. 10.1016\/j.jhepr.2023.100719","journal-title":"JHEP Rep"},{"key":"ref13","article-title":"Clinical Practice Guidelines for Cancer Immunotherapy, Third Edition","year":"2023","unstructured":"Clinical Practice Guidelines for Cancer Immunotherapy, Third Edition. Kanehara & Co., Tokyo; 2023."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10688-0","article-title":"Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics","volume":"18","author":"Zhang N","year":"2024","unstructured":"Zhang N, Li Z, Liu Y, et al.. Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics. Hepatol Int. 2024, 18:1770-80. 10.1007\/s12072-024-10688-0","journal-title":"Hepatol Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465179-optimal-corticosteroid-therapy-based-on-liver-biopsy-for-severe-immune-mediated-hepatitis-during-pembrolizumab-treatment-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:39:25Z","timestamp":1773059965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465179-optimal-corticosteroid-therapy-based-on-liver-biopsy-for-severe-immune-mediated-hepatitis-during-pembrolizumab-treatment-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.104904","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}